Amarin Corporation (AMRN) Proxy filing summary

Executive summary

• Focused on expanding access and adoption of VASCEPA® through a partner-based international model and restructuring to strengthen financials, achieving $70 million in annual cost savings and ending 2025 with $303 million in cash and no debt.

• Strategic initiatives include defending U.S. market leadership, leveraging regional partners for international growth, and maintaining cost-efficient revenue generation.

• Two key shareholder proposals aim to align director compensation with shareholder value (equity vs. cash) and permit electronic delivery of proxy materials for cost and environmental benefits.

Voting matters and shareholder proposals

• Shareholders will vote on re-election of seven directors, advisory approval of executive compensation, appointment of auditors, renewal of share issuance authority, amendment of the stock incentive plan, disapplication of pre-emption rights, and adoption of new articles for electronic notice.

• Proposals 12 and 13 require a 75% supermajority to pass and focus on cost-saving and governance modernization.

• Board recommends voting FOR all director nominees and proposals.

Board of directors and corporate governance

• Board consists of experienced professionals with backgrounds in pharmaceuticals, finance, and operations; all but the CEO are independent.

• Board committees (Audit, Remuneration, Nominating and Corporate Governance) are composed solely of independent directors.

• Code of Conduct and stock ownership guidelines are in place for directors and executives.